StockNews.AI
SNTI
StockNews.AI
74 days

Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC

1. Senti Bio to participate in a fireside chat on June 9, 2025. 2. Senti developing advanced cell and gene therapies with Gene Circuit technology. 3. Management team includes CEO Timothy Lu and CMO Kanya Rajangam. 4. Fireside chat to cover insights on Senti’s clinical developments. 5. Gene Circuits aim to target cancer with precision.

5m saved
Insight
Article

FAQ

Why Bullish?

Senti's participation in a high-profile event can bolster investor confidence. Historical trends show similar stock movements after such engagements.

How important is it?

The announcement is timely and aligns with Senti's clinical and financial growth, boosting prospects.

Why Short Term?

Immediate investor interest may arise from the fireside chat, impacting stock price shortly thereafter.

Related Companies

CRSPZIOPEDITSGMO
Moderated webcast fireside chat with members of Senti management and Chardan senior research analyst, Geulah Livshits, PhD on Monday, June 9th at 3:00 PM ET June 06, 2025 09:05 ET  | Source: Senti Biosciences, Inc. SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will participate in a Virtual Fireside Chat hosted by Chardan Capital Markets, LLC on Monday, June 9, 2025 at 3:00 PM ET. For the fireside chat, Timothy Lu, M.D., Ph.D. Co-Founder and Chief Executive Officer, Kanya Rajangam, M.D., Ph.D. President, Head of Research & Development and Chief Medical Officer, and Jay Cross, Chief Financial Officer of Senti Biosciences will join Chardan senior research analyst, Geulah Livshits, PhD for the moderated discussion. Register for the event here. About Senti BioSenti Bio is a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. The Company’s wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target challenging liquid and solid tumor indications. Senti’s Gene Circuits have been shown preclinically to work in both NK and T cells. Senti Bio has also preclinically demonstrated the potential breadth of Gene Circuits in other modalities and diseases outside of oncology, and continues to advance these capabilities through partnerships.Availability of Other Information About Senti Biosciences, Inc.For more information, please visit the Senti Bio website at www.sentibio.com or follow Senti Bio on X (@SentiBio) and LinkedIn (Senti Biosciences). Investors and others should note that we communicate with our investors and the public using our company website (www.sentibio.com), including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775SNTI@jtcir.com

Related News